IP Library › Granted Patent US 10,272,188
Granted Patent B1
US 10,272,188 · App. 14/803,589 · Granted Apr 30, 2019

Cerebrospinal fluid treatment

Inventors: Mark Geiger (Laguna Niguel, CA); Michael V. Ward (San Ramon, CA)
Assignee: Mensanan Therapeutics LLC
A61M1/1621A61M2202/0464A61M2205/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,272,188
App. No.
14/803,589
Granted
Apr 30, 2019
Kind
B1
Abstract

Provided, among other things, is a method of treating cerebral spinal fluid comprising: (a) utilizing a channel of a pump to draw CSF from a subject's subarachnoid space of the subject's brain or spinal column; (b) subjecting the drawn CSF to membrane dialysis against a dialysate fluid to reduce immune or inflammatory mediators; and (c) utilizing a second channel of the synchronized dual channel pump to return the dialyzed CSF to the subarachnoid space of the subject's brain or spinal column. For example, the pump can be a synchronized dual channel pump. In one embodiment, the method further comprises: (d) removing cellular matter from the CSF to produce reduced cell content CSF, wherein the reduced cell content CSF is subjected to membrane dialysis.

Claims (21)

1. A method of treating cerebral spinal fluid (CSF) comprising:

utilizing a channel of a synchronized dual channel pump to draw out of the body CSF from a subject's subarachnoid space of the subject's brain or spinal column;

removing cellular matter from the drawn, extracorporeal CSF to produce reduced cell content CSF;

subjecting the drawn, filtered, extracorporeal CSF to membrane dialysis against a dialysate fluid to reduce immune or inflammatory mediators; and

utilizing a second channel of the synchronized dual channel pump to return the dialyzed CSF to the subarachnoid space of the subject's brain or spinal column.

2. The method of claim 1 , wherein the reducing cellular material comprises:

flow centrifugation effective to reduce cell content;

subjecting a flow pathway for the CSF to magnetic or electrical fields that cause cells to bias towards flowing through one or more side channels;

flowing the CSF through a charged filter effective to retain human or other vertebrate cells; or

flowing the CSF through a first charged filter effective to retain human or other vertebrate cells and an oppositely charged filter effective to retain human or other vertebrate cells.

3. A method of treating or ameliorating cerebral hemorrhage comprising applying the method of claim 1 to the subject.

4. A method of treating or ameliorating acute brain injury comprising applying the method of claim 1 to the subject.

5. A method of treating or ameliorating encephalitis comprising applying the method of claim 1 to the subject.

6. A method of treating or ameliorating meningitis comprising applying the method of claim 1 to the subject.

7. A method of treating or ameliorating Alzheimer's disease comprising applying the method of claim 1 to the subject.

8. A method of treating or ameliorating Parkinson's disease comprising applying the method of claim 1 to the subject.

9. The method of claim 1 , wherein the reducing cellular material comprises flow centrifugation effective to reduce cell content.

10. The method of claim 1 , wherein the reducing cellular material comprises subjecting a flow pathway for the CSF to magnetic or electrical fields that cause cells to bias towards flowing through one or more side channels.

11. The method of claim 1 , wherein the reducing cellular material comprises flowing the CSF through a filter with pores sized to retain human or other vertebrate cells.

12. The method of claim 1 , wherein the reducing cellular material comprises flowing the CSF through a charged filter effective to retain human or other vertebrate cells.

13. The method of claim 1 , wherein the reducing cellular material comprises flowing the CSF through a first charged filter effective to retain human or other vertebrate cells and separately an oppositely charged filter effective to retain human or other vertebrate cells.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2015
From: GEIGER, MARK; WARD, MICHAEL V.
To: MENSANA THERAPEUTICS LLC
Reel/Frame 036140/0513 →
Continuity (1)
Provisional Application 62027892 · Jul 23, 2014
Cited By (8)
US 12,290,785 US 12,329,930 US 12,337,140 US 12,350,416 US 12,364,952 US 12,576,251 US 12,728,190 US 12,746,377